NCT03369002View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

May 15, 2018

Study Completion Date

May 15, 2018

Conditions

Hepatic Impairment

Interventions

DRUG

seladelpar

Oral single dose 10 mg

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

37920

Vrg & Noccr, Knoxville

55404

DaVita Clinical Research, Minneapolis

80228

DaVita Clinical Research, Lakewood

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY